Clinical trial
Interleukin-2 Plus Bryostatin 1 in Treating Patients With Melanoma or Kidney…
NCT00006022 · Virginia Commonwealth University, Other · Completed
Key facts
| NCT number | NCT00006022 |
|---|---|
| Title | Interleukin-2 Plus Bryostatin 1 in Treating Patients With Melanoma or Kidney Cancer |
| Official title | Phase IA/IB Trial of Modulation of the Biological Response to Interleukin-2 (IL-2) With Bryostatin 1 (BRYO; NSC 339555) |
| Lead sponsor | Virginia Commonwealth University, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Kidney Cancer, Melanoma (Skin) |
| Intervention type | Biological, Drug |
| Interventions | aldesleukin, bryostatin 1 |
| Enrollment | 17 |
| Start date | Sep 1, 2000 |
| Primary completion | Oct 1, 2003 |
| Completion | Jan 1, 2004 |
| First posted | Jan 27, 2003 |
| Last update posted | Dec 14, 2015 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: